Focused On-demand Library for Macrophage-stimulating protein receptor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q04912

UPID:

RON_HUMAN

Alternative names:

CDw136; Protein-tyrosine kinase 8; p185-Ron

Alternative UPACC:

Q04912; A0A087WZG2; B5A944; B5A945; B5A946; B5A947

Background:

The Macrophage-stimulating protein receptor, known alternatively as CDw136, Protein-tyrosine kinase 8, and p185-Ron, plays a pivotal role in cellular processes. It transduces signals from the extracellular matrix to the cytoplasm by binding to MST1 ligand, influencing cell survival, migration, and differentiation. Activation of RON triggers several signaling cascades, including RAS-ERK, PI3 kinase-AKT, and PLCgamma-PKC, crucial for wound healing and the innate immune response.

Therapeutic significance:

Given its involvement in nasopharyngeal carcinoma, understanding the role of the Macrophage-stimulating protein receptor could open doors to potential therapeutic strategies. Its ability to regulate cell migration, proliferation, and survival highlights its potential as a target for innovative cancer treatments.